Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, on Aqueous Humor Dynamics in Laser-Induced Ocular Hypertensive Monkeys

Masahiro Fuwa, Carol B Toris, Shan Fan, Takazumi Taniguchi, Masaki Ichikawa, Noriko Odani-Kawabata, Ryo Iwamura, Kenji Yoneda, Takeshi Matsugi, Naveed K. Shams, Jin Zhong Zhang

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Purpose: To investigate the mechanism of the intraocular pressure (IOP)-lowering effect of a novel selective prostaglandin E2 receptor 2 (EP2) receptor agonist, omidenepag isopropyl (OMDI). Methods: The effect of OMDI on IOP and aqueous humor dynamics was evaluated in cynomolgus monkeys with unilateral laser-induced ocular hypertension. In a crossover manner, the hypertensive eye of each monkey was dosed once daily with 20 μL of either 0.002% OMDI or vehicle. On day 7 of dosing, IOP was measured by pneumatonometry, aqueous humor flow and outflow facility were evaluated by fluorophotometry, and uveoscleral outflow was calculated mathematically. Treatments were compared by paired t-tests. Results: OMDI at 0.002% significantly lowered IOP by 27%, 35%, and 44% at 0.5, 1.5, and 4 h after the last dosing, respectively. There was no difference in aqueous humor flow between vehicle and OMDI treatments. When comparing OMDI to the vehicle treatment, outflow facility and uveoscleral outflow were significantly (P < 0.05) increased by 71% and 176%, respectively. Conclusions: OMDI, a novel IOP-lowering compound, reduced IOP by increasing outflow facility and uveoscleral outflow in nonhuman primates.

Original languageEnglish (US)
Pages (from-to)531-537
Number of pages7
JournalJournal of Ocular Pharmacology and Therapeutics
Volume34
Issue number7
DOIs
StatePublished - Sep 2018

Fingerprint

Aqueous Humor
Intraocular Pressure
Haplorhini
Lasers
Fluorophotometry
Prostaglandin Receptors
Ocular Hypertension
Macaca fascicularis
Dinoprostone
Primates

Keywords

  • EP2 receptor
  • aqueous humor dynamics
  • glaucoma
  • intraocular pressure

ASJC Scopus subject areas

  • Ophthalmology
  • Pharmacology
  • Pharmacology (medical)

Cite this

Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, on Aqueous Humor Dynamics in Laser-Induced Ocular Hypertensive Monkeys. / Fuwa, Masahiro; Toris, Carol B; Fan, Shan; Taniguchi, Takazumi; Ichikawa, Masaki; Odani-Kawabata, Noriko; Iwamura, Ryo; Yoneda, Kenji; Matsugi, Takeshi; Shams, Naveed K.; Zhang, Jin Zhong.

In: Journal of Ocular Pharmacology and Therapeutics, Vol. 34, No. 7, 09.2018, p. 531-537.

Research output: Contribution to journalArticle

Fuwa, Masahiro ; Toris, Carol B ; Fan, Shan ; Taniguchi, Takazumi ; Ichikawa, Masaki ; Odani-Kawabata, Noriko ; Iwamura, Ryo ; Yoneda, Kenji ; Matsugi, Takeshi ; Shams, Naveed K. ; Zhang, Jin Zhong. / Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, on Aqueous Humor Dynamics in Laser-Induced Ocular Hypertensive Monkeys. In: Journal of Ocular Pharmacology and Therapeutics. 2018 ; Vol. 34, No. 7. pp. 531-537.
@article{a40a64f6c7614e789e98c73c5fbfeb6b,
title = "Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, on Aqueous Humor Dynamics in Laser-Induced Ocular Hypertensive Monkeys",
abstract = "Purpose: To investigate the mechanism of the intraocular pressure (IOP)-lowering effect of a novel selective prostaglandin E2 receptor 2 (EP2) receptor agonist, omidenepag isopropyl (OMDI). Methods: The effect of OMDI on IOP and aqueous humor dynamics was evaluated in cynomolgus monkeys with unilateral laser-induced ocular hypertension. In a crossover manner, the hypertensive eye of each monkey was dosed once daily with 20 μL of either 0.002{\%} OMDI or vehicle. On day 7 of dosing, IOP was measured by pneumatonometry, aqueous humor flow and outflow facility were evaluated by fluorophotometry, and uveoscleral outflow was calculated mathematically. Treatments were compared by paired t-tests. Results: OMDI at 0.002{\%} significantly lowered IOP by 27{\%}, 35{\%}, and 44{\%} at 0.5, 1.5, and 4 h after the last dosing, respectively. There was no difference in aqueous humor flow between vehicle and OMDI treatments. When comparing OMDI to the vehicle treatment, outflow facility and uveoscleral outflow were significantly (P < 0.05) increased by 71{\%} and 176{\%}, respectively. Conclusions: OMDI, a novel IOP-lowering compound, reduced IOP by increasing outflow facility and uveoscleral outflow in nonhuman primates.",
keywords = "EP2 receptor, aqueous humor dynamics, glaucoma, intraocular pressure",
author = "Masahiro Fuwa and Toris, {Carol B} and Shan Fan and Takazumi Taniguchi and Masaki Ichikawa and Noriko Odani-Kawabata and Ryo Iwamura and Kenji Yoneda and Takeshi Matsugi and Shams, {Naveed K.} and Zhang, {Jin Zhong}",
year = "2018",
month = "9",
doi = "10.1089/jop.2017.0146",
language = "English (US)",
volume = "34",
pages = "531--537",
journal = "Journal of Ocular Pharmacology and Therapeutics",
issn = "1080-7683",
publisher = "Mary Ann Liebert Inc.",
number = "7",

}

TY - JOUR

T1 - Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, on Aqueous Humor Dynamics in Laser-Induced Ocular Hypertensive Monkeys

AU - Fuwa, Masahiro

AU - Toris, Carol B

AU - Fan, Shan

AU - Taniguchi, Takazumi

AU - Ichikawa, Masaki

AU - Odani-Kawabata, Noriko

AU - Iwamura, Ryo

AU - Yoneda, Kenji

AU - Matsugi, Takeshi

AU - Shams, Naveed K.

AU - Zhang, Jin Zhong

PY - 2018/9

Y1 - 2018/9

N2 - Purpose: To investigate the mechanism of the intraocular pressure (IOP)-lowering effect of a novel selective prostaglandin E2 receptor 2 (EP2) receptor agonist, omidenepag isopropyl (OMDI). Methods: The effect of OMDI on IOP and aqueous humor dynamics was evaluated in cynomolgus monkeys with unilateral laser-induced ocular hypertension. In a crossover manner, the hypertensive eye of each monkey was dosed once daily with 20 μL of either 0.002% OMDI or vehicle. On day 7 of dosing, IOP was measured by pneumatonometry, aqueous humor flow and outflow facility were evaluated by fluorophotometry, and uveoscleral outflow was calculated mathematically. Treatments were compared by paired t-tests. Results: OMDI at 0.002% significantly lowered IOP by 27%, 35%, and 44% at 0.5, 1.5, and 4 h after the last dosing, respectively. There was no difference in aqueous humor flow between vehicle and OMDI treatments. When comparing OMDI to the vehicle treatment, outflow facility and uveoscleral outflow were significantly (P < 0.05) increased by 71% and 176%, respectively. Conclusions: OMDI, a novel IOP-lowering compound, reduced IOP by increasing outflow facility and uveoscleral outflow in nonhuman primates.

AB - Purpose: To investigate the mechanism of the intraocular pressure (IOP)-lowering effect of a novel selective prostaglandin E2 receptor 2 (EP2) receptor agonist, omidenepag isopropyl (OMDI). Methods: The effect of OMDI on IOP and aqueous humor dynamics was evaluated in cynomolgus monkeys with unilateral laser-induced ocular hypertension. In a crossover manner, the hypertensive eye of each monkey was dosed once daily with 20 μL of either 0.002% OMDI or vehicle. On day 7 of dosing, IOP was measured by pneumatonometry, aqueous humor flow and outflow facility were evaluated by fluorophotometry, and uveoscleral outflow was calculated mathematically. Treatments were compared by paired t-tests. Results: OMDI at 0.002% significantly lowered IOP by 27%, 35%, and 44% at 0.5, 1.5, and 4 h after the last dosing, respectively. There was no difference in aqueous humor flow between vehicle and OMDI treatments. When comparing OMDI to the vehicle treatment, outflow facility and uveoscleral outflow were significantly (P < 0.05) increased by 71% and 176%, respectively. Conclusions: OMDI, a novel IOP-lowering compound, reduced IOP by increasing outflow facility and uveoscleral outflow in nonhuman primates.

KW - EP2 receptor

KW - aqueous humor dynamics

KW - glaucoma

KW - intraocular pressure

UR - http://www.scopus.com/inward/record.url?scp=85053061626&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053061626&partnerID=8YFLogxK

U2 - 10.1089/jop.2017.0146

DO - 10.1089/jop.2017.0146

M3 - Article

C2 - 29989843

AN - SCOPUS:85053061626

VL - 34

SP - 531

EP - 537

JO - Journal of Ocular Pharmacology and Therapeutics

JF - Journal of Ocular Pharmacology and Therapeutics

SN - 1080-7683

IS - 7

ER -